Cardlytics, Inc. (NASDAQ:CDLX) Receives $6.92 Consensus Target Price from Brokerages

Shares of Cardlytics, Inc. (NASDAQ:CDLX) have received an average rating of “Hold” from the seven analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $6.92.

A number of equities analysts recently commented on CDLX shares. Craig Hallum raised Cardlytics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 6th. Needham & Company LLC restated a “hold” rating on shares of Cardlytics in a research report on Thursday, November 7th. Finally, Evercore ISI assumed coverage on shares of Cardlytics in a research report on Friday, October 11th. They set an “in-line” rating and a $4.00 price objective for the company.

Cardlytics Trading Up 4.2 %

Shares of NASDAQ CDLX opened at $3.73 on Wednesday. The stock has a market cap of $189.56 million, a P/E ratio of -0.61 and a beta of 1.53. The firm has a 50 day moving average price of $3.90 and a two-hundred day moving average price of $5.38. The company has a debt-to-equity ratio of 2.40, a quick ratio of 1.18 and a current ratio of 1.18. Cardlytics has a 52-week low of $2.89 and a 52-week high of $20.52.

Cardlytics (NASDAQ:CDLX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.18. The business had revenue of $67.06 million during the quarter, compared to the consensus estimate of $57.77 million. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. Cardlytics’s quarterly revenue was down 15.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.26) earnings per share. As a group, equities analysts forecast that Cardlytics will post -1.52 EPS for the current year.

Insider Activity

In other Cardlytics news, CEO Amit Gupta sold 22,607 shares of the firm’s stock in a transaction that occurred on Thursday, October 24th. The stock was sold at an average price of $3.85, for a total value of $87,036.95. Following the completion of the sale, the chief executive officer now owns 178,519 shares of the company’s stock, valued at approximately $687,298.15. This trade represents a 11.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Alexis Desieno sold 25,118 shares of the company’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $3.43, for a total value of $86,154.74. Following the transaction, the chief financial officer now directly owns 116,481 shares in the company, valued at $399,529.83. The trade was a 17.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 68,691 shares of company stock worth $237,767 in the last quarter. 4.40% of the stock is owned by corporate insiders.

Institutional Trading of Cardlytics

A number of hedge funds and other institutional investors have recently bought and sold shares of CDLX. Canton Hathaway LLC increased its holdings in Cardlytics by 95.7% during the 2nd quarter. Canton Hathaway LLC now owns 4,500 shares of the company’s stock worth $37,000 after purchasing an additional 2,200 shares in the last quarter. Atom Investors LP purchased a new position in shares of Cardlytics during the third quarter valued at approximately $33,000. XTX Topco Ltd bought a new stake in Cardlytics during the second quarter worth $107,000. SG Americas Securities LLC purchased a new stake in Cardlytics in the 3rd quarter valued at $45,000. Finally, Intech Investment Management LLC bought a new position in Cardlytics during the 3rd quarter valued at $47,000. Institutional investors own 68.10% of the company’s stock.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.